Recent Updates
Recently added Catalysts
CORT Negative Sentiment Score: 20/100

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Key Takeaway: Corcept Therapeutics is facing a class action lawsuit due to allegations of securities fraud linked to the failure of their product relacorilant to receive FDA approval. The lawsuit claims that the company misled investors about the likelihood of FDA approval, leading to substantial losses when news of a Complete Response Letter emerged. As a result, Corcept's stock price plummeted by over 50%. Investors affected during the specified class period have until April 21, 2026, to respond to the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • Corcept Therapeutics faces a class action lawsuit due to securities fraud.
  • The company's recent failure to gain FDA approval for relacorilant led to a significant stock price drop.
  • Share prices fell by over 50% following the FDA's Complete Response Letter issuance.
  • Investors have until April 21, 2026, to file for lead plaintiff status, indicating ongoing legal troubles.

Full Press Release Details

NEW YORK and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
If you purchased shares of Corcept and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-cort/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 21, 2026.
Corcept and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The complaint alleges that, during the Class Period, the Company represented to investors that there was a high likelihood that one of its lead new product candidates, relacorilant, would receive approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s New Drug Application (“NDA”) submission. However, on December 31, 2025, the Company disclosed that the FDA had issued a Complete Response Letter (“CRL”) regarding the NDA for relacorilant and that it had “concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”
On this news, the price of Corcept’s shares plummeted by $35.40 per share, or 50.4%, from a closing price of $70.20 on December 30, 2025, to a closing price of $34.80 on December 31, 2025.
The case is Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
1100 Poydras St., Suite 960
New Orleans, LA 70163
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Tags

Securities Litigation

Frequently Asked Questions

What is the deadline to file a lead plaintiff application for Corcept?

The deadline to file a lead plaintiff application in the Corcept case is April 21, 2026.

What caused the drop in Corcept's share price?

Corcept's share price fell after the FDA issued a Complete Response Letter for relacorilant.

Who should contact Kahn Swick & Foti for legal rights information?

Investors who suffered losses from Corcept's shares during the class period should contact KSF.

What lawsuit does the article discuss?

The article discusses a securities class action lawsuit against Corcept Therapeutics Incorporated.

Which law firm is leading the Corcept securities lawsuit?

Kahn Swick & Foti, LLC is leading the securities class action lawsuit against Corcept.

Last updated: Mar 11, 2026